EP 2021350 A1 20090211 - PHOSPHORYLATED A2A RECEPTOR AGONISTS
Title (en)
PHOSPHORYLATED A2A RECEPTOR AGONISTS
Title (de)
PHOSPHORYLIERTE ADENOSIN-A2A-REZEPTORAGONISTEN
Title (fr)
AGONISTES DU RÉCEPTEUR A2A PHOSPHORYLÉ
Publication
Application
Priority
- EP 2007052716 W 20070321
- EP 06111493 A 20060321
- US 81940006 P 20060710
- EP 07727192 A 20070321
Abstract (en)
[origin: WO2007107598A1] A phosphorylated A<SUB>2A</SUB> receptor agonist providing agonist properties on the A<SUB>2A</SUB> receptor after dephosphorylation the phosphorylated A<SUB>2A</SUB> receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5'-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e. g. inflammatory events. In particular, compounds of formula (I) are also disclosed.
IPC 8 full level
A61K 31/7076 (2006.01); A61P 37/06 (2006.01); C07H 19/20 (2006.01)
CPC (source: EP US)
A61P 19/00 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 37/06 (2017.12 - EP); C07H 19/20 (2013.01 - EP US)
Citation (search report)
See references of WO 2007107598A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK RS
DOCDB simple family (publication)
WO 2007107598 A1 20070927; EP 2021350 A1 20090211; EP 2021350 B1 20161221; US 2010048501 A1 20100225; US 2014288019 A1 20140925; US 9505796 B2 20161129
DOCDB simple family (application)
EP 2007052716 W 20070321; EP 07727192 A 20070321; US 201314108010 A 20131216; US 29398307 A 20070321